AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31751776 — intervention group
Group type: COMPARATOR
Intervention: In-person care
Number of subjects: 0
Study 31751776 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-centered care
Number of subjects: 0
Study 31751776 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study 30590857 — intervention group
Group type: EXPERIMENTAL
Intervention: Reboxetine (4 mg) plus hyoscine butylbromide (20 mg)
Number of subjects: 10
Study 30590857 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 29268677 — intervention group
Group type: EXPERIMENTAL
Intervention: Arabic numeral anchor
Number of subjects: 0
Study 29268677 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal format anchor
Number of subjects: 0
Study 29268677 — intervention group
Group type: EXPERIMENTAL
Intervention: Numeric information presentation
Number of subjects: 0
Study 26446726 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based Parent-child Interaction Therapy (PCIT)
Number of subjects: 60
Study 26446726 — intervention group
Group type: COMPARATOR
Intervention: Standard pediatric primary care
Number of subjects: 60
Study 23875989 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive retention strategies including obtaining extensive contact information, building relationships with case managers and social workers, contacting jails and prisons, text messaging, e-mailing, messaging via social networking sites, identifying appointments via electronic medical record, and field outreach to treatment facilities, residences, and parks.
Number of subjects: 100
Study 23875989 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive retention strategies
Number of subjects: 100
Study 22765333 — intervention group
Group type: EXPERIMENTAL
Intervention: Psycho-educational intervention
Number of subjects: 115
Study 22765333 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control group
Number of subjects: 115
Study 19228214 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine inferior alveolar nerve block (IANB) with supplementary articaine buccal infiltration (2 mL of articaine 4% with epinephrine 1:100,000)
Number of subjects: 36
Study 19228214 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine inferior alveolar nerve block (IANB) alone
Number of subjects: 36
Study 19228214 — intervention group
Group type: COMPARATOR
Intervention: Buccal infiltration with articaine
Number of subjects: 36
Study 19228214 — intervention group
Group type: COMPARATOR
Intervention: Dummy buccal injection
Number of subjects: 36
Study 17255371 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant (NK1 antagonist)
Number of subjects: 0
Study 17255371 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15371667 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine (CsA) once a day (OD group)
Number of subjects: 54
Study 15371667 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine (CsA) twice a day (BD group)
Number of subjects: 54
Study 11436232 — intervention group
Group type: EXPERIMENTAL
Intervention: Chalk-based antimicrobial dentifrice
Number of subjects: 0
Study 11436232 — intervention group
Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 0
Study 9620812 — intervention group
Group type: EXPERIMENTAL
Intervention: Furlow double-reversing Z-plasty palatoplasty
Number of subjects: 608
Study 9620812 — intervention group
Group type: COMPARATOR
Intervention: von Langenbeck procedure with intravelar velarplasty
Number of subjects: 608
Study 7533998 — intervention group
Group type: EXPERIMENTAL
Intervention: Costimulatory stromal receptors identified in thymuses and TETs
Number of subjects: 0
Study 3065101 — intervention group
Group type: EXPERIMENTAL
Intervention: Bumetanide (group A, n = 13)
Number of subjects: 37
Study 3065101 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (group B, n = 12)
Number of subjects: 37
Study 3065101 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of bumetanide and spironolactone (group C, n = 12)
Number of subjects: 37
Study 3065101 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 37
Study 28939500 — intervention group
Group type: EXPERIMENTAL
Intervention: AV re-education via smartphone
Number of subjects: 283
Study 28939500 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 283
Study 28939500 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-L PEG
Number of subjects: 283
Study 26833454 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of diacetyl boldine (DAB) serum at night and DAB/TGF‐β1 biomimetic oligopeptide‐68/sunscreen cream in the morning and at noon
Number of subjects: 40
Study 26833454 — intervention group
Group type: COMPARATOR
Intervention: 2% and 4% hydroquinone cream (HQ)
Number of subjects: 40
Study 24655469 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive transfusion protocol with a trigger of hemoglobin ≤ 6 g/dL; transfusion acceptable for hemoglobin 6-8 g/dL and only with evidence of end-organ ischemia for hemoglobin 8-10 g/dL.
Number of subjects: 409
Study 24655469 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfusion for hemoglobin 6-8 g/dL
Number of subjects: 409
Study 24655469 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfusion for hemoglobin 8-10 g/dL with evidence for end-organ ischemia
Number of subjects: 409
Study 24655469 — intervention group
Group type: EXPERIMENTAL
Intervention: Avoidance of allogeneic transfusion
Number of subjects: 409
Study 23091107 — intervention group
Group type: EXPERIMENTAL
Intervention: Belief-type query
Number of subjects: 171
Study 23091107 — intervention group
Group type: COMPARATOR
Intervention: Combination query
Number of subjects: 171
Study 23091107 — intervention group
Group type: COMPARATOR
Intervention: Frequency-type query
Number of subjects: 171
Study 20544311 — intervention group
Group type: EXPERIMENTAL
Intervention: WATCHMAN device for left atrial appendage closure
Number of subjects: 0
Study 20544311 — intervention group
Group type: COMPARATOR
Intervention: Surgical exclusion of the left atrial appendage
Number of subjects: 0
Study 20544311 — intervention group
Group type: COMPARATOR
Intervention: Novel pharmacologic agents
Number of subjects: 0
Study 20544311 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 0
Study 18278183 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene therapy
Number of subjects: 24523
Study 15811089 — intervention group
Group type: EXPERIMENTAL
Intervention: pioglitazone 15 mg
Number of subjects: 70
Study 15811089 — intervention group
Group type: EXPERIMENTAL
Intervention: pioglitazone 30 mg
Number of subjects: 70
Study 15811089 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 70
Study 12220418 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal therapy
Number of subjects: 0
Study 12220418 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 0
Study 10598598 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine (6 microg x kg(‐1)min(‐1))
Number of subjects: 17
Study 8566605 — intervention group
Group type: EXPERIMENTAL
Intervention: Perfusion with camostate (synthetic protease inhibitor)
Number of subjects: 9
Study 8566605 — intervention group
Group type: EXPERIMENTAL
Intervention: Perfusion with protein
Number of subjects: 9
Study 8566605 — intervention group
Group type: COMPARATOR
Intervention: Perfusion with camostate with protein
Number of subjects: 9
Study 8566605 — intervention group
Group type: EXPERIMENTAL
Intervention: Perfusion with amino acids
Number of subjects: 9
Study 8566605 — intervention group
Group type: COMPARATOR
Intervention: Perfusion with camostate with amino acids
Number of subjects: 9
Study 8877232 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative amoxycillin
Number of subjects: 70
Study 8877232 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative cefaclor
Number of subjects: 70
Study 8877232 — intervention group
Group type: COMPARATOR
Intervention: No antibiotic (control)
Number of subjects: 70
Study 2878274 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese acupuncture
Number of subjects: 24
Study 2878274 — intervention group
Group type: COMPARATOR
Intervention: Placebo acupuncture
Number of subjects: 24
Study 28984089 — intervention group
Group type: EXPERIMENTAL
Intervention: Spritztube (ST)
Number of subjects: 47
Study 28984089 — intervention group
Group type: COMPARATOR
Intervention: Fastrach laryngeal mask airway (FT‐LMA)
Number of subjects: 47
Study 26486704 — intervention group
Group type: EXPERIMENTAL
Intervention: DEC 6 mg/kg + ALB 400 mg + IVM 200 μg/kg
Number of subjects: 24
Study 26486704 — intervention group
Group type: COMPARATOR
Intervention: DEC 6 mg/kg + ALB 400 mg
Number of subjects: 24
Study 26595748 — intervention group
Group type: EXPERIMENTAL
Intervention: Omit NRTIs
Number of subjects: 360
Study 26595748 — intervention group
Group type: COMPARATOR
Intervention: Add NRTIs
Number of subjects: 360
Study 22747197 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycle ergometry training (30-min once weekly for 6 weeks)
Number of subjects: 23
Study 22046325 — intervention group
Group type: EXPERIMENTAL
Intervention: Education + Pedometer
Number of subjects: 43
Study 22046325 — intervention group
Group type: COMPARATOR
Intervention: Education only
Number of subjects: 43
Study 18989711 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent dexamethasone (DEXA)
Number of subjects: 16
Study 17163477 — intervention group
Group type: EXPERIMENTAL
Intervention: VelaSmooth
Number of subjects: 20
Study 17163477 — intervention group
Group type: COMPARATOR
Intervention: TriActive
Number of subjects: 20
Study 12971029 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg valdecoxib
Number of subjects: 34
Study 12971029 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg valdecoxib
Number of subjects: 34
Study 12971029 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg valdecoxib
Number of subjects: 34
Study 12971029 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 10849221 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor skills of blind children
Number of subjects: 40
Study 10849221 — intervention group
Group type: COMPARATOR
Intervention: Control group of sighted children
Number of subjects: 40
Study 7720361 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence including mechanism information
Number of subjects: 0
Study 7720361 — intervention group
Group type: COMPARATOR
Intervention: Conflicting evidence matching in covariation values
Number of subjects: 0
Study 2166308 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.025 mmol Gd-DTPA/kg body weight
Number of subjects: 33
Study 2166308 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05 mmol Gd-DTPA/kg body weight
Number of subjects: 33
Study 2166308 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mmol Gd-DTPA/kg body weight
Number of subjects: 33
Study 2166308 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mmol Gd-DTPA/kg body weight (further increase in group 3)
Number of subjects: 33
Study 7325201 — intervention group
Group type: EXPERIMENTAL
Intervention: Goldmann applanation tonometry without fluorescein (Ophthetic only)
Number of subjects: 100
Study 7325201 — intervention group
Group type: COMPARATOR
Intervention: Goldmann applanation tonometry with fluorescein (Fluress)
Number of subjects: 100
Study 30856101 — intervention group
Group type: EXPERIMENTAL
Intervention: OPEN procedures
Number of subjects: 35
Study 30856101 — intervention group
Group type: COMPARATOR
Intervention: MIS procedures
Number of subjects: 35
Study 28079569 — intervention group
Group type: EXPERIMENTAL
Intervention: Standing Cough Stress Test (CST)
Number of subjects: 60
Study 28079569 — intervention group
Group type: COMPARATOR
Intervention: Supine Cough Stress Test (CST)
Number of subjects: 60
Study 26200978 — intervention group
Group type: EXPERIMENTAL
Intervention: Nodal-irradiation group
Number of subjects: 4004
Study 26200978 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 4004
Study 23816325 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality-controlled CPR using a monitor-defibrillator with a quality analysis feature
Number of subjects: 187
Study 23816325 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (control group not explicitly mentioned)
Number of subjects: 187
Study 21661426 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus (Tac) in double therapy (plus steroids)
Number of subjects: 100
Study 21661426 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine microemulsion (CyA‐me) in triple therapy (plus steroids and azathioprine)
Number of subjects: 100
Study 21661426 — intervention group
Group type: EXPERIMENTAL
Intervention: Conversion to Tac from CyA‐me
Number of subjects: 100
Study 19748641 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory physical exercise program (aerobic and anaerobic)
Number of subjects: 106
Study 19748641 — intervention group
Group type: COMPARATOR
Intervention: Conventional information about diet and exercise
Number of subjects: 106
Study 16529046 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy
Number of subjects: 0
Study 14693085 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin and cloxacillin (group 1)
Number of subjects: 61
Study 14693085 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin and genticin (group 2)
Number of subjects: 61
Study 14693085 — intervention group
Group type: COMPARATOR
Intervention: No systemic chemo prophylaxis (control group)
Number of subjects: 61
Study 14693085 — intervention group
Group type: COMPARATOR
Intervention: Comparison of treatment groups vs control
Number of subjects: 61
Study 11768726 — intervention group
Group type: EXPERIMENTAL
Intervention: metoprolol (METO)
Number of subjects: 64
Study 11768726 — intervention group
Group type: EXPERIMENTAL
Intervention: amlodipine (AMLO)
Number of subjects: 64
Study 11768726 — intervention group
Group type: EXPERIMENTAL
Intervention: temocapril (TEMO)
Number of subjects: 64
Study 11768726 — intervention group
Group type: EXPERIMENTAL
Intervention: doxazosin (DOXA)
Number of subjects: 64
Study 11768726 — intervention group
Group type: EXPERIMENTAL
Intervention: trichlormethiazide (TCTZ)
Number of subjects: 64
Study 11768726 — intervention group
Group type: EXPERIMENTAL
Intervention: nifedipine (NIFE)
Number of subjects: 64
Study 9246799 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative urinalysis with New Use criteria
Number of subjects: 42
Study 9246799 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative urinalysis and estimated New Uses
Number of subjects: 42
Study 9246799 — intervention group
Group type: COMPARATOR
Intervention: Qualitative urinalysis
Number of subjects: 42
Study 8153735 — intervention group
Group type: EXPERIMENTAL
Intervention: Midnight catheter removal
Number of subjects: 0
Study 8153735 — intervention group
Group type: COMPARATOR
Intervention: 6 AM catheter removal
Number of subjects: 0
Study 2849682 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (18 g/day)
Number of subjects: 0
Study 2849682 — intervention group
Group type: COMPARATOR
Intervention: Olive oil supplement
Number of subjects: 0
Study 31506877 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung protective ventilation (LPV) with a tidal volume of 6 ml/IBW and PEEP of 10 cm H2O
Number of subjects: 24
Study 31506877 — intervention group
Group type: COMPARATOR
Intervention: Conventional ventilation (CV) with a tidal volume of 10 ml/IBW and PEEP of 4 cm H2O
Number of subjects: 24
Study 31506877 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung protective ventilation (LPV)
Number of subjects: 24
Study 31506877 — intervention group
Group type: COMPARATOR
Intervention: Conventional ventilation (CV)
Number of subjects: 24
Study 31203670 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic approach
Number of subjects: 12
Study 31203670 — intervention group
Group type: COMPARATOR
Intervention: Midline tendon‐split approach
Number of subjects: 12
Study 29231549 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint transcutaneous electric stimulation combined with conventional intravenous general anesthesia (No.2 group, 50 cases)
Number of subjects: 146
Study 29231549 — intervention group
Group type: COMPARATOR
Intervention: Conventional intravenous general anesthesia (No.1 group, 48 cases)
Number of subjects: 146
Study 29231549 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint transcutaneous electric stimulation combined with conventional intravenous general anesthesia (No.3 group, 48 cases)
Number of subjects: 146
Study 26423737 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated management using ready-to-use therapeutic food (RUTF) with a decreasing ration and health maintenance messages.
Number of subjects: 1957
Study 26423737 — intervention group
Group type: COMPARATOR
Intervention: Standard management using fortified blended flour for MAM and RUTF for SAM.
Number of subjects: 1957
Study 26423737 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated management protocol.
Number of subjects: 1957
Study 26423737 — intervention group
Group type: COMPARATOR
Intervention: Standard management protocol.
Number of subjects: 1957
Study 23549132 — intervention group
Group type: EXPERIMENTAL
Intervention: NeuroFlo device
Number of subjects: 192
Study 23549132 — intervention group
Group type: COMPARATOR
Intervention: Best medical treatment (control)
Number of subjects: 192
Study 21450069 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity screening (alone or in combination with diet)
Number of subjects: 0
Study 21450069 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruit and vegetable screening
Number of subjects: 0
Study 21450069 — intervention group
Group type: EXPERIMENTAL
Intervention: All three types of screening
Number of subjects: 0
Study 18505968 — intervention group
Group type: EXPERIMENTAL
Intervention: FEC-P (fluorouracil, epirubicin, cyclophosphamide followed by weekly paclitaxel)
Number of subjects: 1246
Study 18505968 — intervention group
Group type: COMPARATOR
Intervention: FEC (fluorouracil, epirubicin, and cyclophosphamide)
Number of subjects: 1246
Study 18505968 — intervention group
Group type: EXPERIMENTAL
Intervention: FEC-P
Number of subjects: 1246
Study 18505968 — intervention group
Group type: COMPARATOR
Intervention: FEC
Number of subjects: 1246
Study 17160915 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone 8 mg/day
Number of subjects: 72
Study 17160915 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone 4 mg/day
Number of subjects: 72
Study 17160915 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone 4 mg/day and 8 mg/day
Number of subjects: 72
Study 17160915 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 12706027 — intervention group
Group type: EXPERIMENTAL
Intervention: Total hip arthroplasty (THA)
Number of subjects: 20
Study 10764700 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 U Botulinum toxin
Number of subjects: 118
Study 10764700 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 U Botulinum toxin (initial injection)
Number of subjects: 118
Study 10764700 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 U Botulinum toxin (second injection after 30 days)
Number of subjects: 118
Study 10764700 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 U Botulinum toxin
Number of subjects: 118
Study 8842654 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylitol (0.25 g kg‐1 h‐1)
Number of subjects: 30
Study 8842654 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid (0.5 g h‐1)
Number of subjects: 30
Study 8842654 — intervention group
Group type: COMPARATOR
Intervention: Ringer's lactate
Number of subjects: 30
Study 1569343 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine (AZT)
Number of subjects: 50
Study 1569343 — intervention group
Group type: EXPERIMENTAL
Intervention: Acid treatment of plasma
Number of subjects: 50
Study 1569343 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 2411876 — intervention group
Group type: COMPARATOR
Intervention: No speech therapy
Number of subjects: 52
Study 2411876 — intervention group
Group type: EXPERIMENTAL
Intervention: Porch Index of Communicative Ability test score at 4 weeks
Number of subjects: 52
Study 29017742 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative anterior thigh temperature
Number of subjects: 46
Study 26569427 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 81
Study 26569427 — intervention group
Group type: COMPARATOR
Intervention: Neuromuscular protocol adherence
Number of subjects: 81
Study 24401754 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 000IU vitamin D orally once a week for 10 weeks
Number of subjects: 61
Study 24401754 — intervention group
Group type: COMPARATOR
Intervention: 600 000IU single intramuscular injection
Number of subjects: 61
Study 23140417 — intervention group
Group type: EXPERIMENTAL
Intervention: Menaquinone-4 (MK-4) 420 μg (945 nmol) single dose
Number of subjects: 0
Study 23140417 — intervention group
Group type: EXPERIMENTAL
Intervention: Menaquinone-7 (MK-7) 420 μg (647 nmol) single dose
Number of subjects: 0
Study 23140417 — intervention group
Group type: EXPERIMENTAL
Intervention: Menaquinone-4 (MK-4) 60 μg (135 nmol) consecutive administration for 7 days
Number of subjects: 0
Study 23140417 — intervention group
Group type: EXPERIMENTAL
Intervention: Menaquinone-7 (MK-7) 60 μg (92 nmol) consecutive administration for 7 days
Number of subjects: 0
Study 20361620 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended preoperative course of radiotherapy plus 5-fluorouracil chemomodification (group 1)
Number of subjects: 62
Study 20361620 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended preoperative course of radiotherapy plus 5-fluorouracil chemomodification and hyperthermia (group 2)
Number of subjects: 62
Study 17373916 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin 1600 mg/day
Number of subjects: 80
Study 17373916 — intervention group
Group type: COMPARATOR
Intervention: Rifaximin 1200 mg/day
Number of subjects: 80
Study 17373916 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80
Study 16378561 — intervention group
Group type: EXPERIMENTAL
Intervention: Fusidic acid gel 1% (one drop, four times daily for one week)
Number of subjects: 181
Study 16378561 — intervention group
Group type: COMPARATOR
Intervention: Placebo (one drop, four times daily for one week)
Number of subjects: 181
Study 16378561 — intervention group
Group type: EXPERIMENTAL
Intervention: Fusidic acid gel 1%
Number of subjects: 181
Study 16378561 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 181
Study 12212881 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular Coke
Number of subjects: 17